logo-loader
viewBiocept Inc

Full interview: Biocept 'one of the first' liquid biopsy providers to detect cancer biomarkers in fluid around brain

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the California-based company's Target Selector liquid biopsy tests are now available to detect cancer biomarkers in cerebrospinal fluid. Nall says the company has also managed to win a US patent for its liquid biopsy cancer testing technology.

Quick facts: Biocept Inc

Price: 0.338 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $14.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Biocept pursuing new strategy with a physician association using its liquid...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the liquid biopsy test provider has struck up an agreement with an undisclosed independent physician association in California to provide liquid biopsy testing services to its physicians and patients. Nall says this is the first value-based...

1 week, 1 day ago

2 min read